Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

M Pharmaceutical maps out strategy for weight loss drug

Tuesday, November 29, 2016 9:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

M Pharmaceutical Inc (CNSX:MQ) has unveiled its strategy to commercialise its side-effect-free version of orlistat, the weight-loss drug marketed as alli and Xenical.

The focus initially will be the previously-approved indication for adolescent obesity along with new treatment areas non-alcoholic fatty liver disease and for non-alcoholic steatohepatitis.

M Pharma’s C-103 is a combination of orlistat, simethicone (which reduces bloating) and activated charcoal.

Together they work to mitigate the bowel-related problems with a product that otherwise has a clean bill of health.

Orlistat is the best-selling weight loss medication of all time with peak sales of over $900mln. It has a strong safety profile and is approved by the US Food & Drug Administration.

According to the World Health Organization, 1.9bn adults globally are overweight or obese, which adds up to a ticking healthcare time-bomb.  

“Obesity increases the risk of heart disease, diabetes, kidney complications, joint disorders and certain cancers,” said M Pharma chief executive Gary Thompson.

“M Pharma has a unique opportunity with C-103 to make a significant impact in treating this world epidemic.” 

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.